These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19348555)

  • 21. Strategies for preventing influenza: future perspectives in influenza vaccine technology.
    Zuccotti GV; Fabiano V
    Expert Opin Biol Ther; 2011 Jan; 11(1):1-4. PubMed ID: 21133814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of inactivated influenza vaccine in children less than 5 years of age over multiple influenza seasons: a case-control study.
    Joshi AY; Iyer VN; St Sauver JL; Jacobson RM; Boyce TG
    Vaccine; 2009 Jul; 27(33):4457-61. PubMed ID: 19490957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should health-care providers in the United States have access to influenza vaccines formulated for the southern hemisphere?
    Strikas RA; Kozarsky PE; Reed C; Kapella BK; Freedman DO
    J Travel Med; 2008; 15(6):442-6. PubMed ID: 19090800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress with human H5N1 vaccines: a perspective from industry.
    Palache B; Krause R
    Expert Rev Vaccines; 2009 Apr; 8(4):391-400. PubMed ID: 19348556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emulsion-based adjuvants for influenza vaccines.
    Vogel FR; Caillet C; Kusters IC; Haensler J
    Expert Rev Vaccines; 2009 Apr; 8(4):483-92. PubMed ID: 19348563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.
    Ambrozaitis A; Groth N; Bugarini R; Sparacio V; Podda A; Lattanzi M
    Vaccine; 2009 Oct; 27(43):6022-9. PubMed ID: 19666152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
    Chiu SS; Chan KH; Tu W; Lau YL; Peiris JS
    Vaccine; 2009 Jul; 27(35):4834-9. PubMed ID: 19523908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse events associated with intranasal influenza vaccine in the United States.
    Vasu N; Ghaffari G; Craig ET; Craig TJ
    Ther Adv Respir Dis; 2008 Aug; 2(4):193-8. PubMed ID: 19124371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
    Reisinger KS; Block SL; Izu A; Groth N; Holmes SJ
    J Infect Dis; 2009 Sep; 200(6):849-57. PubMed ID: 19673652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A universal epitope-based influenza vaccine and its efficacy against H5N1.
    Adar Y; Singer Y; Levi R; Tzehoval E; Perk S; Banet-Noach C; Nagar S; Arnon R; Ben-Yedidia T
    Vaccine; 2009 Mar; 27(15):2099-107. PubMed ID: 19356612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine decisions loom for new flu strain.
    Butler D
    Nature; 2009 May; 459(7244):144-5. PubMed ID: 19444174
    [No Abstract]   [Full Text] [Related]  

  • 34. Relationship of Th1/Th2 cell balance with the immune response to influenza vaccine during pregnancy.
    Yamaguchi K; Hisano M; Isojima S; Irie S; Arata N; Watanabe N; Kubo T; Kato T; Murashima A
    J Med Virol; 2009 Nov; 81(11):1923-8. PubMed ID: 19774681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
    Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
    J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap.
    Heldens JG; Pouwels HG; Derks CG; Van de Zande SM; Hoeijmakers MJ
    Vaccine; 2009 Sep; 27(40):5530-7. PubMed ID: 19607950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influenza vaccination coverage among children aged 6 months--18 years - eight immunization information system sentinel sites, United States, 2008-09 influenza season.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Oct; 58(38):1059-62. PubMed ID: 19798018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intent to receive influenza A (H1N1) 2009 monovalent and seasonal influenza vaccines - two counties, North Carolina, August 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(50):1401-5. PubMed ID: 20032923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valuing influenza vaccine: medical, economic, and social benefits.
    Poland GA
    Clin Infect Dis; 2009 Feb; 48(3):299-301. PubMed ID: 19115975
    [No Abstract]   [Full Text] [Related]  

  • 40. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.
    Rosenberg M; Sparks R; McMahon A; Iskander J; Campbell JD; Edwards KM
    Vaccine; 2009 Jul; 27(32):4278-83. PubMed ID: 19450636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.